Prix Axe Compute Inc. (POAI)

Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal, and associated products. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 23 full-time employees. The company went IPO on 2009-12-18. The Company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy when a tumor sample responds to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Through AI, it uses its proprietary biobank of 150,000+ cancer tumor samples, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of drug development. The firm offers a suite of solutions for oncology drug development from early discovery to clinical trials.